Setron

Quick links to important sections

Setron

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Setron

What is Setron?

Setron is a medication belonging to a class of drugs known as serotonin 5-HT3 receptor antagonists. It is primarily used to prevent and manage nausea and vomiting associated with specific medical treatments or surgical procedures.

How Setron Works

The medication functions by blocking the action of serotonin, a natural chemical in the body that can trigger the vomiting reflex. Serotonin is released in the small intestine and the brain during certain physiological stresses. By binding to specific 5-HT3 receptors, Setron prevents these signals from reaching the vomiting center in the brain, thereby reducing the sensation of nausea.

Clinical Applications

Setron is utilized in several clinical contexts where nausea and vomiting are common side effects:

  • Chemotherapy: It is used to manage both acute and delayed nausea resulting from cancer treatments.
  • Radiation Therapy: It helps control symptoms in patients undergoing radiation, particularly when the treatment area involves the abdomen.
  • Post-Surgical Recovery: It is administered to prevent or treat postoperative nausea and vomiting (PONV) following general anesthesia.

Forms of the Medication

Setron is available in various formulations to accommodate different patient needs and clinical settings. These include oral tablets, orally disintegrating tablets that dissolve on the tongue, and intravenous solutions for direct administration by healthcare professionals.

What side effects are possible with Setron?

Possible Side Effects and Safety Information

The safety profile of Setron (Granisetron) is documented and classified by government regulatory agencies, such as the FDA and the EMA, based on clinical trial data. The most frequently reported adverse reactions are classified as Very Common or Common.


Official Frequency Classification

Classification Common Adverse Reactions
Very Common (ge 1/10) Headache, Constipation
Common (ge 1/100 to <1/10) Diarrhoea, Insomnia, Elevated hepatic transaminases
Uncommon (ge 1/1,000 to <1/100) QT prolongation, Hypersensitivity reactions, Extrapyramidal reactions

System-Organ Classes and Serious Reactions

The reported effects are categorized across multiple System-Organ Classes, including the Nervous System (e.g., Headache), Gastrointestinal Tract (e.g., Constipation, Diarrhoea), and the Cardiac System.

Clinically significant adverse reactions documented in the regulatory label include Serotonin Syndrome, particularly when Setron is used concomitantly with other serotonergic medicines (like certain antidepressants or opioids). Furthermore, QT interval prolongation and severe Hypersensitivity Reactions are explicitly noted as potentially serious safety considerations.


Safety Considerations for Special Populations

Specific regulatory cautions apply to patients with pre-existing cardiac conditions due to the documented risk of QT prolongation. Caution is also warranted for patients who have undergone abdominal surgery, as Setron may reduce lower bowel motility, potentially masking the presence of a progressive ileus or gastric distention. Use during pregnancy or lactation is generally advised to be avoided as a precautionary measure.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose information for Setron (Granisetron), based strictly on government regulatory documents.

Overdose scope Regulatory Statement
Documented overdose presentations Overdose manifestations documented include headache and non-specific symptoms such as agitation.
Physiological systems affected Severe overdose is documented to affect the central nervous system (CNS), potentially leading to seizures and coma, and the cardiovascular system, with risk of fast, slow, or irregular heartbeat.
Dose-related or exposure-related factors Single intravenous doses up to 38.5 mg have been administered in clinical trials without resulting in clinically significant effects. A risk of Serotonin syndrome is associated with high-dose exposure when combined with other serotonergic agents.
Emergency-response statements Official guidance requires calling emergency services and the poison control helpline immediately if overdose is suspected.
When immediate medical help is required Immediate medical treatment is required for any serious symptoms, including collapse, having a seizure, difficulty breathing, or inability to be awakened.

Overdose Classifications (High-Level)

Classification Field Regulatory Statement
Severity classification Overdose has the potential for serious and life-threatening outcomes, involving specific cardiac and neurological events.
Overdose-context constraints Management is constrained by the official statement that no specific antidote is known.

Resulting Overdose Structure

  • Overdose may involve serious manifestations affecting the CNS, such as seizures and coma, and the cardiovascular system, including an irregular heartbeat.
  • Management must be symptomatic and supportive, as regulatory documents confirm that no specific antidote is known.
  • Immediate medical attention is required for any severe signs or if the individual collapses or has difficulty breathing.
  • Dialysis is not effective for treating overdose due to the drug's volume of distribution.

Regulatory documents define the Setron overdose profile by recognizing the potential for life-threatening neurological and cardiac consequences, which mandates the need for immediate emergency intervention. Because management is limited to supportive care and no specific antidote is available, seeking urgent medical help is the primary required action when serious manifestations occur.

Therapeutic Uses of Setron

What Setron Treats: Main Uses and Benefits

Setron is commonly used to help with acute or disruptive episodes of nausea and vomiting. It is relevant for easing symptoms related to systemic imbalance associated with acute or disruptive episodes.

Setron is primarily applied across three therapeutic domains: supportive care during chemotherapy, management of sickness associated with radiation therapy, and addressing Postoperative Nausea and Vomiting (PONV) following anesthesia and surgery. It helps ease the overall symptom burden in situations presenting with acute or disruptive symptom patterns.

“This antiemetic is relevant when symptom clusters are anticipated to be intense or disruptive, including both acute and delayed phases.”

By providing symptomatic relief for these manifestations, the medication contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Heightened Nausea and Vomiting The relevant use is for symptoms related to physical discomfort caused by procedures associated with acute or disruptive symptom patterns, managing both the sudden and fluctuating manifestations.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Setron?

Use of Setron is absolutely contraindicated for patients with a known hypersensitivity to the active ingredient, Granisetron, or to any of the product's components. The oral formulation is also contraindicated with the concurrent use of apomorphine.

Age-Group Eligibility: The medicine is approved for adults across all labeled uses. Pediatric use is established for children aged 2 years and above for acute chemotherapy-induced nausea and vomiting (CINV). Safety and efficacy have not been established in children younger than 2 years of age or for post-operative nausea and vomiting (PONV) in any pediatric group. Older adults generally require no special dose adjustments.

Condition-Based Restrictions: Setron must be used with caution in patients with pre-existing cardiac conduction disorders, such as arrhythmias, or those with electrolyte abnormalities. Patients with signs of sub-acute intestinal obstruction require monitoring. While use is acceptable in patients with renal impairment, a degree of caution is advised for those with hepatic impairment.

Pregnancy and Lactation: Use during pregnancy is generally preferable to avoid and is recommended only if clearly needed. Breast-feeding should be discontinued during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Setron (Granisetron) based on governmental regulatory sources.


Pharmacodynamic and Contraindicated Combinations

Interaction Entity Official Regulatory Restriction
Apomorphine Co-administration is contraindicated due to official reports of profound hypotension and loss of consciousness.
Serotonergic Drugs (e.g., SSRIs, SNRIs, Tramadol) Concurrent use is associated with a risk of Serotonin Syndrome.
Drugs that Prolong the QT Interval Documented potential for additive QTc prolongation effects.

Pharmacokinetic and Substance Interactions

Interaction Entity Official Regulatory Outcome
Phenobarbital (CYP Inducer) Officially results in a measured 25% increase in the total plasma clearance of Granisetron.
Ketoconazole (CYP Inhibitor) In vitro data suggests potential for decreased metabolism (clinical effect unknown).
Alcohol May worsen central nervous system effects such as drowsiness.

No mandatory timing or separation requirements are specified for the administration of other medicinal products in the regulatory documentation. Interaction cautions regarding QTc prolongation apply to individuals with pre-existing cardiac conditions or electrolyte abnormalities.

Mechanism of Action

Setron is a small molecule that functions as a highly selective competitive antagonist at the 5-HT3 receptor. This specific serotonin receptor subtype is a ligand-gated cation channel located on neuronal membranes in both the peripheral and central nervous systems. The primary biological targets are the vagal afferent nerve terminals in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) in the area postrema of the brainstem.

Setron competitively binds to the extracellular ligand-binding site of the 5-HT3 receptor. This interaction blocks the binding of the endogenous agonist, serotonin (5-HT), which is released from enterochromaffin cells in the gut following certain stimuli. By occupying the binding site, Setron stabilizes the receptor in an inactive, closed conformation, preventing the ligand-gated ion channel from opening. This blockade of the 5-HT3 channel inhibits the resultant influx of cations, thereby preventing the depolarization and subsequent generation of an action potential in the vagal afferent neurons. This reduction in the firing of vagal afferent nerve signals, combined with direct antagonism at central 5-HT3 receptors in the CTZ, modulates afferent neurological input to the central emetic center, consequently decreasing efferent nerve signaling that regulates visceral function.

Dosage and Administration Information

The use of Setron (Granisetron) is defined by guidelines that standardize its route, timing, and dosage for administration. The medication is used via multiple routes, including Oral (tablets or solution), Intravenous (IV) injection or infusion, and a Transdermal patch system. A distinct Subcutaneous (SC) extended-release injection is also part of the options for adult patients.

Administration guidelines mandate a prophylactic schedule, requiring the medicine to be given before the anticipated event. For chemotherapy-induced nausea and vomiting (CINV), the standard IV dose is 10 mcg/kg administered within 30 minutes before the start of chemotherapy. Oral regimens are often 1 mg twice daily or 2 mg once daily, taken up to one hour prior to treatment, with the total duration limited to approximately seven days.

The transdermal patch system is a single-use application, typically applied 24 to 48 hours prior to chemotherapy, and is designed to remain in place for up to seven days. For patients with renal impairment, the frequency of the SC extended-release injection requires adjustment in moderate cases, limited to no more than once every 14 days. Specific guidelines define a 10 mcg/kg IV dose for pediatric patients aged 2 to 16. For IV use, the solution may be administered undiluted over 30 seconds or diluted with standard solutions for a longer infusion time (e.g., 5 minutes).

Recent Clinical Evidence

Research Evidence: Overview of Studies for Setron


Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

The primary research base for Setron in this context consists of numerous Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were conducted during periods of increased symptom activity, specifically focusing on patients receiving chemotherapy regimens that are known to cause significant sickness (emetogenic regimens). Researchers examined Setron in research exploring the prevention of acute (first 24 hours) and delayed (up to five days) sickness associated with cancer treatment. Key outcomes related to systemic or functional imbalance were monitored, such as the achievement of a Complete Response (no vomiting or need for additional antiemetic medication).

However, certain research limitations have been noted. Much of the early evidence focused heavily on specific, older chemotherapy regimens. Furthermore, follow-up durations were limited; there is limited information for long-term outcomes beyond the five-day delayed phase. Data for certain groups, such as very young children or those with specific comorbidities, also remain insufficient, with evidence quality varying across studies.


Evidence for Use in Postoperative Nausea and Vomiting (PONV)

The research into Setron for sickness associated with surgery and general anesthesia is also largely based on Randomized Controlled Trials (RCTs) and subsequent Meta-analyses. These studies were applied in research contexts involving fluctuating or unstable symptoms during the immediate recovery period. Research examined Setron for the prevention of sickness when symptoms were anticipated to be acute or disruptive, and in research examining the treatment of sickness after it had already occurred. Outcomes related to physical discomfort were monitored over defined time intervals, typically ranging up to 24 hours post-surgery.

What remains uncertain relates primarily to standardization. Limited consensus on optimal dosing across the full spectrum of different surgical types has been observed in some studies. The research exploring Setron's use for the treatment of established PONV symptoms is sometimes more limited in scope compared to the studies focused on prevention.

Key Studies & References Granisetron Hydrochloride Injection, USP, for intravenous use - Full Prescribing Information

Frequently Asked Questions (FAQ)

Common questions about Setron (FAQ)

Q: How long does it typically take to feel the effects of Setron?

A: Setron is administered prophylactically, meaning it is given before the event that is expected to cause nausea and vomiting. According to official product information, control of these symptoms has been observed to last over 24 hours after a single intravenous dose. The medicine is generally used to prevent symptoms (prophylactically) rather than to treat established symptoms.

Q: Can Setron affect my ability to drive or operate machinery?

A: Regulatory documents advise caution when performing tasks that require mental alertness. This is because side effects such as drowsiness (somnolence), dizziness, and blurred vision are listed in the medicine's product information. Awareness of individual response to the medicine is advised prior to engaging in activities like driving or operating machinery.

Q: Is Setron considered safe for long-term use?

A: The medicine is typically indicated for short-term use related to specific therapies, such such as chemotherapy or radiation. For example, oral use is generally limited to up to seven consecutive days. Official evidence supporting outcomes for extended long-term use (beyond a few weeks) is limited.

Q: Why do some people need to take Setron for a long time?

A: The length of time Setron is used is determined by the duration of the underlying therapy, such as the full course of chemotherapy or radiotherapy. Some specific formulations, like the transdermal patch system, are designed to remain effective for an extended period, such as up to seven days.

Q: Is it normal to have mild stomach upset when starting Setron?

A: Official information indicates that both Diarrhoea and Constipation are listed as common adverse events associated with this medicine. Stomach pain is also listed as a reported side effect, which means that some forms of stomach discomfort are possible.

Q: How long does Setron stay in the body after the last dose?

A: The rate at which the medicine is processed by the body is described by its elimination half-life. This measure of time is reported in official sources to be approximately 3 to 14 hours for Setron.

Q: Can Setron be crushed or split if the tablets are large?

A: Regulatory guidance on splitting or crushing tablets is generally cautious. Official sources indicate that crushing or splitting standard tablets is not recommended, especially since alternative forms like liquid solutions or orally disintegrating tablets are available.

Q: If I stop taking Setron, are there common withdrawal effects?

A: The official product information lists adverse events primarily describing those occurring during the administration period or shortly thereafter. Withdrawal effects are not listed or discussed as a common or specific adverse event in the regulatory documentation.

Q: Is it common to feel tired when first taking Setron?

A: Yes, regulatory documents list a few effects that relate to feeling tired. Both Asthenia (a condition of abnormal physical weakness or lack of energy) and somnolence (drowsiness) are reported as Common adverse events in the official prescribing information. This indicates that effects related to tiredness are possible, as documented in the official prescribing information.

Q: What happens if I forget to take a dose of Setron?

A: Guidance on missed doses is to contact a healthcare professional for specific instructions and safety advice. Patient materials advise against taking extra doses to compensate for a missed one.

Q: Is there a generic version of Setron available?

A: Yes, the active ingredient, Granisetron, is available in generic forms. However, some highly specific formulations, such as sustained-release injectable forms, may still only be available as a branded product.

Q: Does Setron affect blood pressure or heart rhythm?

A: Official information indicates that this medicine has the potential to cause QT interval prolongation, which is a change in the heart's electrical activity. In terms of blood pressure, Hypertension (raised blood pressure) is listed as a Common side effect, while Hypotension (low blood pressure) is reported as Rare.

Q: Does Setron cause problems with sleep?

A: Official product information lists Insomnia (difficulty sleeping) as a Common adverse event. This indicates that problems with sleep are possible, as documented in the regulatory files.

Q: Is there a risk of allergy or hypersensitivity reactions to Setron?

A: Yes, Hypersensitivity reactions (allergic reactions) are explicitly noted in the product information. These reactions are classified as Uncommon adverse events, as documented in the product information.

Q: Is there any official guidance on taking Setron with common beverages like coffee or juice?

A: Official regulatory documentation does not specify mandatory timing or separation requirements for the administration of the medicine with common beverages like coffee or juice. The only specific substance interaction caution highlighted in the label is regarding alcohol.

Q: Are there restrictions on Setron use based on age or weight?

A: Yes, age is a factor, as the medicine's safety has not been established for children under 2 years old. Weight-based dosing ( mcg/kg) is specified for the intravenous form in both adults and pediatric patients, indicating that body weight is considered a factor in use conditions.

Q: Is Setron commonly used in hospitals or only for outpatient care?

A: The medicine is approved for multiple routes of administration, including Intravenous (IV) injection/infusion and Subcutaneous (SC) extended-release injection. The availability of these parenteral forms suggests its use in clinical and hospital settings, in addition to oral and transdermal forms used for outpatient care.

Q: What is the likelihood of a serious side effect from Setron?

A: Clinical trial summaries cited in regulatory reviews report that Serious Adverse Events (SAEs) occurred at a rate of approximately 4.5% to 9.4% for oral and transdermal forms in the studies examined. SAEs are serious adverse events documented in the trials.

Q: Does taking Setron affect fertility?

A: Non-clinical studies were conducted to assess reproductive effects. Evidence from these studies indicated that the medicine had no harmful effects on reproductive performance or fertility in the species studied (rats).

Q: What does official guidance say about missing multiple doses of Setron?

A: Guidance for managing missed doses is to contact a healthcare professional for specific safety advice. Patient materials state that patients should avoid attempting to take extra doses to compensate for those that have been missed.

How should Setron be stored and disposed of?

Storage and Handling

Setron (Ondansetron/Granisetron) products must be stored strictly according to official regulatory requirements to maintain stability. The medication should be kept in its original container, tightly closed, and stored at the specified temperature—either Controlled Room Temperature (20°C to 25°C) or refrigerated (2°C to 8°C), depending on the specific product form.

All forms must be protected from light and excessive moisture; for instance, injection vials should be kept in their carton, and oral forms should not be stored in humid areas like a bathroom. Orally disintegrating tablets require careful handling using dry hands just before administration.

Stability and Disposal

For injectable solutions, the diluted product must be discarded after 24 hours. All forms must be secured out of the sight and reach of children. Setron is not on the list of medications recommended for flushing. Disposal must follow regulatory guidelines, preferably using an authorized drug take-back program. If a take-back option is unavailable, the medication must be mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a container before placing in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Setron found in:

A-Z Index: